Science & Enterprise subscription

Follow us on Twitter

  • A challenge competition with a total purse of $1 million seeks a new type of face mask that people will be eager to…
    about 12 hours ago
  • New post on Science and Enterprise: Challenge Seeks Next-Generation Face Mask #Science #Business
    about 12 hours ago
  • An experimental vaccine to prevent Covid-19 infections, given as a nasal spray, produces immune responses in tests…
    about 20 hours ago
  • New post on Science and Enterprise: Immune Responses Shown in Covid-19 Nasal Vaccine #Science #Business
    about 20 hours ago
  • A clinical trial began enrolling participants to collect real world evidence on a digital therapy designed to relie…
    about 2 days ago

Please share Science & Enterprise

Trial to Test App Alerting for Dementia-Linked Drugs

Phone and keyboard


15 July 2019. A mobile and computer app that alerts older citizens about a class of drugs associated with Alzheimer’s disease will soon be tested in a clinical trial. A team at Indiana University and Purdue University in Indianapolis, and the affiliated Regenstrief Institute, received a 5-year, $3.5 million grant from National Institute on Aging, part of National Institutes of Health, to fund the trial.

The trial will test an app designed for smartphones, tablets, and desk or laptop system called Brain Safe that aims to reduce exposure of older individuals to anticholinergic drugs. Anticholinergics block the actions of a neurotransmitter, a signaling chemical in the brain, called acetylcholine found in motor neurons to stimulate muscle movement, and plays a key role in memory and cognition. These drugs are found in medications to treat a wide range of disorders from depression and sleep disorders to allergies and heart failure.

Researchers led by Richard Holden, director of Indiana’s Health Innovation Lab and a medical school faculty member, developed Brain Safe to alert people who take anticholinergic drugs, particularly older persons, about their risks. The team says one in three older people in the U.S. take anticholinergic drugs, despite increasing evidence that higher use of these drugs is associated with cognitive impairment, Alzheimer’s disease, and other forms of dementia.

Brain Safe is based on research on medical decision making that shows older individuals are interested and concerned about side-effects of over-the-counter drugs, but did not know about age-related risks associated with anticholinergics. The study team, including Holden, constructed a conceptual model of medical decision-making behavior that helped design Brain Safe. A later project tested the feasibility of an early version of the mobile app that show software of this kind is easy to use and can encourage older individuals to raise the issue of anticholinergics with their doctors.

The latest app includes an calculator to gauge an individual’s risk of exposure to anticholinergic drugs, tips to start a conversation with one’s doctor about anticholinergics, and multimedia content. The trial to test Brain Safe aims to enroll 700 individuals, with participants randomly assigned to use Brain Safe or an unrelated WebMD Health Assessment. Individuals taking part will be assessed before using the apps, then at 6 and 12 months for anticholinergic exposure, verified by dispensing records.

“Interventions to lower this risk are urgently needed,” says Holden in a university statement. “We hope this app will raise awareness and provide information to people, allowing them to take action to protect their brain health.”

More from Science & Enterprise:

*     *     *

Please share Science & Enterprise ...

Comments are closed.